Literature DB >> 26893756

Inflammatory myofibroblastic tumor with RANBP2 and ALK gene rearrangement with bland cytological features mimicking desmoid-type fibromatosis: A case report and review of the literature.

Yu-Hua Huang1, Yu-Feng Tian2, Chien-Feng Li3.   

Abstract

Here, we present an uncommon case of inflammatory myofibroblastic tumor (IMT) involving the mesentery. The tumor was composed of loosely arranged round-to-spindle-shaped tumor cells with amphophilic cytoplasm in an inflammatory and myxoid background. The mitotic activity was low (1 per 50 high-power fields) and the tumor cells lacked cellular atypism. Immunohistochemically, the tumor cells demonstrated strong nuclear membranous staining with anaplastic lymphoma kinase (ALK). In situ hybridization for ALK gene rearrangement revealed a splitting apart of the two signals within the tumor cells. Reverse transcription-polymerase chain reaction revealed that the tumor harbored a ran-binding protein 2 (RANBP2)-ALK rearrangement. IMTs are usually characterized by epithelioid-to-round cells featuring increased mitotic activity, occasionally demonstrating unusual tumor cells and more aggressive clinical behavior. To date, 23 IMTs have been reported with RANBP2 and ALK gene rearrangements. However, the present case demonstrated indolent cytological features, leading to a difficulty in differentiating it from desmoid-type fibromatosis.

Entities:  

Keywords:  anaplastic lymphoma kinase; inflammatory myofibroblastic tumor; ran-binding protein 2; round cell

Year:  2016        PMID: 26893756      PMCID: PMC4734286          DOI: 10.3892/ol.2016.4082

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  11 in total

1.  Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

Authors:  James E Butrynski; David R D'Adamo; Jason L Hornick; Paola Dal Cin; Cristina R Antonescu; Suresh C Jhanwar; Marc Ladanyi; Marzia Capelletti; Scott J Rodig; Nikhil Ramaiya; Eunice L Kwak; Jeffrey W Clark; Keith D Wilner; James G Christensen; Pasi A Jänne; Robert G Maki; George D Demetri; Geoffrey I Shapiro
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

2.  Preparation of cells from formalin-fixed, paraffin-embedded tissue for use in fluorescence in situ hybridization (FISH) experiments.

Authors:  Stanislawa Weremowicz; Deborah E Schofield
Journal:  Curr Protoc Hum Genet       Date:  2007-01

3.  Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK.

Authors:  Adrián Mariño-Enríquez; Wei-Lien Wang; Angshumoy Roy; Dolores Lopez-Terrada; Alexander J F Lazar; Christopher D M Fletcher; Cheryl M Coffin; Jason L Hornick
Journal:  Am J Surg Pathol       Date:  2011-01       Impact factor: 6.394

4.  Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor.

Authors:  Zhigui Ma; D Ashley Hill; Margaret H Collins; Stephan W Morris; Janos Sumegi; Ming Zhou; Craig Zuppan; Julia A Bridge
Journal:  Genes Chromosomes Cancer       Date:  2003-05       Impact factor: 5.006

5.  An inflammatory myofibroblastic tumor in liver with ALK and RANBP2 gene rearrangement: combination of distinct morphologic, immunohistochemical, and genetic features.

Authors:  Sung-Ting Chen; Jen-Chieh Lee
Journal:  Hum Pathol       Date:  2008-08-12       Impact factor: 3.466

6.  Epithelioid inflammatory myofibroblastic sarcoma arising in the pleural cavity.

Authors:  Yoshiki Kozu; Mitsuhiro Isaka; Yasuhisa Ohde; Kengo Takeuchi; Takashi Nakajima
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-01-24

7.  Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases.

Authors:  C M Coffin; J Watterson; J R Priest; L P Dehner
Journal:  Am J Surg Pathol       Date:  1995-08       Impact factor: 6.394

8.  RANBP2 and CLTC are involved in ALK rearrangements in inflammatory myofibroblastic tumors.

Authors:  Ankita S Patel; Kathleen M Murphy; Anita L Hawkins; Julie S Cohen; Patricia P Long; Elizabeth J Perlman; Constance A Griffin
Journal:  Cancer Genet Cytogenet       Date:  2007-07-15

Review 9.  Inflammatory myofibroblastic tumours: where are we now?

Authors:  B C Gleason; J L Hornick
Journal:  J Clin Pathol       Date:  2007-10-15       Impact factor: 3.411

Review 10.  Inflammatory myofibroblastic tumor with RANBP2 and ALK gene rearrangement: a report of two cases and literature review.

Authors:  Jian Li; Wei-hua Yin; Kengo Takeuchi; Hong Guan; Yu-hua Huang; John K C Chan
Journal:  Diagn Pathol       Date:  2013-09-13       Impact factor: 2.644

View more
  3 in total

Review 1.  Clinical Utility of In Situ Hybridization Assays in Head and Neck Neoplasms.

Authors:  Peter P Luk; Christina I Selinger; Wendy A Cooper; Annabelle Mahar; Carsten E Palme; Sandra A O'Toole; Jonathan R Clark; Ruta Gupta
Journal:  Head Neck Pathol       Date:  2018-11-22

2.  CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma.

Authors:  Karen L MacKenzie; Toby N Trahair; Ashleigh M Fordham; Jinhan Xie; Andrew J Gifford; Carol Wadham; Lisa T Morgan; Emily V A Mould; Mitali Fadia; Lei Zhai; Hassina Massudi; Zara S Ali; Glenn M Marshall; Robyn E Lukeis; Jamie I Fletcher
Journal:  Br J Cancer       Date:  2020-07-20       Impact factor: 7.640

3.  A recurrent inflammatory myofibroblastic tumor patient with two novel ALK fusions: a case report.

Authors:  Xiumei Xu; Ling Li; Yaxuan Zhang; Fanfan Meng; Hongmei Xie; Ruiqi Duan
Journal:  Transl Cancer Res       Date:  2022-09       Impact factor: 0.496

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.